D. Valmori et al., Naturally occurring human lymphocyte antigen-A2 restricted CD8+T-cell response to the cancer testis antigen NY-ESO-1 in melanoma patients, CANCER RES, 60(16), 2000, pp. 4499-4506
Cancer testis (CT) antigens are particularly interesting candidates for can
ter vaccines. However, T-cell reactivity to CT antigens has been detected o
nly occasionally In cancer patients, even after vaccination. A new group of
CT antigens has been recently identified using the SEREX technique based o
n immunoscreening of tumor cDNA expression libraries with autologous sera.
We have used fluorescent HLA-A2/peptide tetramers containing an optimized a
ntigenic peptide to directly identify HLA-A2-restricted CD8(+) T cells spec
ific for the SEREX-defined CT antigen NY-ESO-1 in melanoma patients. High f
requencies of NY-ESO-1-specific CD8+ T cells were readily detected in pepti
de-stimulated peripheral blood mononuclear cells as well as in lymphocytes
infiltrating melanoma lesions from patients with measurable antibody respon
ses to NY-ESO-1. NY-ESO-1-specific CD8(+) T cells were also detectable in p
eptide-stimulated peripheral blood mononuclear cells from some seronegative
patients. Whereas the frequencies of NY-ESO-1-specific CD8(+) T cells in c
irculating lymphocytes were usually below the limit of detection by tetrame
r staining, the presence of NY-ESO-I CD8+ T cells displaying a memory pheno
type was clearly detectable ex vivo in blood from a seropositive patient ov
er an extended period of time. These results indicate that sustained CD8(+)
T-cell responses to CT antigens can naturally occur both locally and syste
mically in melanoma patients.